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Abstract
We obtained cDNA chimeras between Na/glucose cotransporter (SGLT1) and the homologous Na/myo-inositol
cotransporter (SMIT) by creating random chimeras in plasmids. Of 12 chimeras, two were functional when expressed in
Xenopus laevis oocytes but, upon sequencing, only one of them (C1) produced an actual chimeric protein. In C1, the first 69
amino acids of SGLT1 were replaced by the corresponding 50 amino acids of SMIT. C1 transports the same sugars as does
SGLT1. C1’s affinity for all sugar substrates was systematically increased by a factor of 3.3 þ 0.4 but the Vmax was diminished
by a factor of 15^40. In contrast, the cotransport affinity for Na was unchanged. The surface expression of C1 was one
seventh that of SGLT1, which explains part of the reduced Vmax and implies a significant reduction in turnover rate. N-
terminal truncated constructs of SGLT1 cDNA showed that deleting amino acids 2^14 does not affect cotransporter activity,
but that the pentapeptide T14RPVET19 is important for normal levels of SGLT1 current. The main result of a kinetic analysis
of the systematic increase in apparent affinity for sugars, together with the intact Na apparent affinity, suggests enhanced
access to the sugar binding site in C1. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
The ¢rst mammalian cotransporter cDNA to be
cloned was the Na/glucose cotransporter [1]. Since
SGLT1 cDNA can be expressed at high levels in
Xenopus laevis oocytes, where both steady-state and
transient currents can be measured, this system has
been used extensively for analyzing the kinetics of
this cotransporter [2^7]. This approach has, however,
provided little information about the nature of the
binding sites for Na and sugars or the mechanism
by which the transporter functions.
Some knowledge about the structure of this trans-
porter has been obtained from sequence alignments
of SGLT1 to homologous proteins. SGLT1 belongs
to a group of proteins that transports a wide range
of substrates (e.g. glucose, iodine, proline and pan-
tothenic acid) and displays considerable diversity in
the carboxyl halves of the sequences [8,9]. In con-
trast, the amino terminal halves display considerable
similarity, though not within their extreme terminal
regions.
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Within the family of transporters homologous to
SGLT1, the Na/myo-inositol cotransporter (SMIT)
displays a high degree of identity (46%) and similar-
ity (80%) to SGLT1 [10]. The physiological function
of this protein is well established and it has been
shown to display substrate-dependent currents
when expressed in Xenopus oocytes [11]. Both
SGLT1 and SMIT are speci¢cally inhibited by phlor-
izin, albeit with di¡erent Ki values, and the proteins
display di¡erent substrate speci¢cities although their
substrates are chemically similar. The creation of chi-
meras between homologous proteins has been used
to deduce structure^function relationships for di¡er-
ent membrane proteins, such as G-protein-coupled
receptors [12,13], ion channels [14] and transporters
[15,16]. In the case of SGLT1, a single paper reports
the production of a chimera composed of amino
acids 1^380 of porcine SGLT2 (low-a⁄nity Na/glu-
cose cotransporter) and 381^662 of porcine SGLT1
[17]. This chimera maintained the a⁄nity and the
sugar speci¢city of SGLT1, but the a⁄nity for Na
was intermediate between that of the two original
proteins. The possibility that the sugar binding site
was determined by the carboxyl terminal half of the
protein was later con¢rmed by the observation of
some sugar transport through a cDNA construct ex-
pressing only the last ¢ve transmembrane segments
of the protein [18].
In this study, we employed a method previously
described for rapidly creating multiple chimeras be-
tween related proteins [19], which requires cleavage
of a circular, recombinant plasmid between two ho-
mologous cDNA inserts placed ‘head-to-toe’. We fo-
cus here on a functional chimera where the initial 69
amino acids of SGLT1 were replaced by the corre-
sponding 50 amino acids of SMIT. This chimera
(C1) transports KMG but not myo-inositol and has
been functionally characterized in detail.
2. Materials and methods
2.1. Chimera generation
Preparation of chimeric transporters was done as
described by Moore and Blakely [19]. One initial
construct was pSPORT^SMIT, generously provided
by Dr. Moo Kwan (Johns Hopkins School of Med-
icine, Baltimore, MA). The other was pMT21^
SGLT1 [6] which expresses human SGLT1 in eu-
karyotic cells. Site-directed mutagenesis was used to
create a MluI site in the 5P-untranslated region of
SGLT1. The mutated recombinant was then cleaved
with MluI followed by a partial cleavage with PstI
(due to a PstI polymorphism near the 3P end of our
human SGLT1) to yield a linear fragment containing
a small gap between the PstI and MluI sites imme-
diately upstream of the full-length SGLT1 insert.
The full-length SMIT insert was removed from
pSPORT using MluI and Sse8387I, and ligated into
the cleaved pMT21^SGLT1. The pMT21^SMIT^
SGLT1 DNA was then linearized at two unique re-
striction sites between the two cDNAs (SnaBI and
XbaI) and dephosphorylated, and the linear DNA
was puri¢ed from an agarose gel. 50^100 ng of pu-
ri¢ed DNA were transformed by heat shock into 200
Wl of competent DH5K bacteria. Bacterial colonies
which imported and recircularized the linearized
plasmid were selected using carbenicillin (50 Wg/ml).
Plasmids were puri¢ed from these colonies and those
which displayed an insert size between 2400 and 3100
bp were used for intranuclear injection of Xenopus
oocytes. The plasmids were subsequently analyzed by
restriction enzyme mapping to locate the approxi-
mate position of the SMIT^SGLT1 junction. Di-
deoxy sequencing (Sequenase v2.0, Amersham Phar-
macia Biotech, Baie d’Urfe¤ Canada) was performed
to determine the precise junction between the por-
tions of SMIT and SGLT1 in selected plasmids.
2.2. SGLT1 deletion mutants
The creation of a series of deletion mutants at
the amino terminus was performed using the poly-
merase chain reaction. The following oligonucleo-
tides (Alpha DNA, Montreal, Canada) were used:
5P-Trunc, CATGGTGGCAGCGGAATTCAGGCT-
CG; 3P-Trunc#1, ACCTGGAGCCCCAAGACCA-
CCGCG; 3P-Trunc#2, ACCACCGCGGTCACCC-
GGCCT; 3P-Trunc#3, CGGCCTGTTGAGACCC-
ACGAGCTCATTC; 3P-Trunc#4, CACGAGCTC-
ATTCGCAATGCAGCCGAT. The 5P-Trunc oligo
was used in each reaction and coded for the reverse
complement of the 5P-untranslated region and the
starting methionine codon. Deletion mutants
SGLT1v2^4 (i.e. amino acids 2^4 are deleted),
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SGLT1v2^9, SGLT1v2^14 and SGLT1v2^19 were
created by performing PCR [20] using the 5P-Trunc
oligonucleotide with the 3P-Trunc#1, 3P-Trunc#2, 3P-
Trunc#3 and 3P-Trunc#4 oligonucleotides, respec-
tively. Sequencing results showed that the
SGLT1v2^4 deletion mutant actually produced an
SGLT1v2^6 deletion: it was used and is listed as
such below. Sequencing of the other deletion mutants
indicated that the products were as originally
planned.
2.3. Oocyte injection and maintenance
Oocytes were removed from Xenopus laevis adults
(Xenopus One, Ann Arbor, MI) under anesthesia
with 0.13% 3-aminobenzoic acid ethyl ester; the cells
were defolliculated, injected and maintained as pre-
viously described [21]. Each plasmid preparation was
diluted to 65 ng/Wl in water containing 65 ng/Wl of a
recombinant pMT21 vector which expressed secreted
alkaline phosphatase (pMT21^SEAP), for injection
of 4.6 nl aliquots into oocytes. The detection of
SEAP activity in the external milieu of isolated oo-
cytes was used to select oocytes which were express-
ing nuclear-injected DNA [22]. Later experiments re-
placed SEAP with a cDNA that expressed green
£uorescent protein [23] for identi¢cation of oocytes
which expressed the injected DNA [24]. No di¡er-
ences have been observed between glucose-induced
currents in oocytes expressing either 300 pg of
pMT21^SGLT1 plasmid or 10 ng of in vitro tran-
scribed SGLT1 mRNA aside from greater variability
in the level of expressed currents when DNA is ex-
pressed. No glucose-induced currents were seen in
either uninjected oocytes or water-injected oocytes.
2.4. Two microelectrode voltage-clamp
Oocyte currents were measured with the two mi-
croelectrode voltage-clamp technique as described
[21]. Only cells with resting membrane potentials
more negative than 335 mV were used. The standard
bath solutions contained (in mM): NaCl 90, KCl 3,
MgCl2 0.82, CaCl2 0.74, HEPES 5, pH 7.6. Oocytes
were held at 350 mV and transmembrane currents
were measured in response to changes in bath sugar,
Na, and phlorizin concentrations. A data acquisi-
tion system (R.C. Electronics, Santa Barbara, CA)
was used to send voltage pulse protocols and simul-
taneously record current and voltage signals. Eleven
alternating 150 ms duration pulses separated by 500
ms periods at the resting potential (350 mV) were
used; the voltage range covered was from 3175 to
+75 mV. Current and voltage traces were analyzed
by averaging the signal in a window of 20 ms posi-
tioned at the end of the pulse, well after all capaci-
tative transients have decayed.
2.5. Phlorizin binding measurements
Phlorizin (Pz) binding studies were performed us-
ing control (non-injected) and mRNA-injected oo-
cytes at 5^7 days following injection. Oocytes were
preincubated (8^12 per vial) at room temperature for
15 min in Barth’s solution prior to assay. The pre-
incubation medium was replaced with 0.5 ml of me-
dium containing tracer amounts of 3H-phlorizin
(2 WCi/ml, speci¢c activity 55 Ci/mmol, New England
Nuclear, Boston, MA) and incubated for another 15
min period. Binding was stopped by rinsing four
times with 2 ml of ice-cold Barth’s solution. Oocytes
were then transferred individually into scintillation
vials and dissolved by agitation in 0.2 ml 10% SDS
for 4 h after which 5 ml of Beta-Blend scintillation
cocktail (ICN, Montreal Canada) was added. Triti-
um levels were measured using liquid scintillation
counting. Speci¢c binding on SGLT1-expressing oo-
cytes is completely displaced by excess cold phlorizin
(50 WM).
Statistical signi¢cance was assessed using Student’s
paired or unpaired t-test, as appropriate.
3. Results
3.1. Production of chimeric cDNAs
After transformation with the linearized pMT21^
SMIT^SGLT1 plasmid, 23 carbenicillin-resistant
bacterial colonies were isolated. Restriction digest
analysis revealed that 11 of the recombinant plas-
mids contained inserts which were too long to code
for a true chimeric cDNA and that all recombination
in the other 12 plasmids occurred within or prior to
the ¢rst 80 amino acids of SGLT1. The recombinant
plasmids were injected into oocytes which were sub-
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sequently exposed to K-methylglucose (KMG) or
myo-inositol (substrates for SGLT1 and SMIT, re-
spectively). None of the oocytes evinced signi¢cant
currents (s 5 nA) upon application of 5 mM myo-
inositol, but two of the cDNA clones produced
measurable currents upon exposure to 5 mM
KMG; the other 10 clones were not further studied.
Of the two positive clones (C1 and C5), one (C5)
produced a protein identical to SGLT1 since the re-
combination occurred in the untranslated region of
SGLT1, whereas the other (C1) expressed a true chi-
meric protein. Sequencing of the C1 cDNA revealed
a protein largely identical to SGLT1, but where the
N-terminal 69 amino acids of SGLT1 were replaced
by the ¢rst 50 amino acids of SMIT (Fig. 1A); re-
combination occurred somewhere within the DNA
coding for the subsequent six amino acids, which
are identical in the two sequences. Analysis of the
C1 and SGLT1 sequences produced similar hydro-
pathy values [25] and suggested a similar membrane
topology for both C1 and SGLT1 (Fig. 1B), indicat-
ing that the extracellular N-terminal region and the
two initial transmembrane domains of C1 are derived
from SMIT.
3.2. Sugar-induced currents
Fig. 2A shows the currents recorded when non-
injected oocytes and oocytes expressing SGLT1,
Fig. 1. Comparison of the SGLT1 and C1 protein sequences.
The chimera C1 is identical to SGLT1 except that the ¢rst 69
amino acids of SGLT1 are replaced by the ¢rst 50 amino acids
of SMIT. (A) Alignment of the initial amino acid sequences of
SGLT1 and C1. The bold characters indicate the portion of the
C1 sequence that is derived from SMIT. The numbers refer to
position in the SGLT1 sequence. Similar and identical residues
are indicated by one or two dots, respectively. (B) Hydropathic
pro¢le of the amino terminal region of the protein sequences of
SGLT1 and C1. Proposed membrane-spanning domains are
shown by striped bars. The analysis was performed using win-
dows between 11 and 21 amino acids.
Fig. 2. Sugar-induced currents via SGLT1 and C1. (A) Record-
ings of KMG- and myo-inositol-induced currents in SGLT1-,
SMIT- and C1-expressing oocytes as well as in control oocytes.
DNA-injected oocytes were exposed to 5 mM KMG or myo-
inositol in saline Barth’s solution and the membrane potential
was held at 350 mV. (B) Current^voltage relationships of the
steady-state currents in C1- and SGLT1-expressing oocytes
which are induced by addition of 1 mM glucose (n = 6). The in-
set shows the C1 current^voltage relationship using a dimin-
ished ordinate scale.
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SMIT or C1 were perfused with solutions containing
5 mM KMG or 5 mM myo-inositol. Perfusion with
5 mM myo-inositol caused inward currents of 50 nA
in SMIT-expressing oocytes and of 10 nA in SGLT1-
expressing oocytes, but no current was seen with C1-
expressing oocytes. Perfusion of SGLT1- and C1-ex-
pressing oocytes with 5 mM KMG produced inward
currents that were absent in both control and SMIT-
expressing oocytes. The KMG-induced current in C1-
expressing oocytes was 15 to 40 times smaller than
that in SGLT1-expressing oocytes, with observed
variations in this ratio being primarily due to di¡er-
ent batches of oocytes. The current/voltage (I^V) re-
lationships of the D-glucose dependent currents
(shown in Fig. 2B) were deduced by subtracting cur-
rents measured in the absence of 1 mM glucose from
those measured in the presence of glucose. As others
have previously shown [2,11], the glucose-induced
inward current of SGLT1 increases with increasingly
negative membrane potentials between +50 and
3100 mV and seems to reach a maximal level at
highly negative potentials. The glucose-induced cur-
rent for C1 also increases from +50 to 3100 mV, but
increases even more between 3100 and 3175 mV.
Interestingly, the published I^V relationship for
SMIT behaves in a similar manner [11].
To examine the e¡ects of altering the amino ter-
minal region of the chimera on the glucose-binding
site, C1- and SGLT1-expressing oocytes were incu-
bated with varying concentrations of KMG. As
shown in Fig. 3B, the activation of the C1 cotran-
sport current by KMG can be described by a Michae-
lis^Menten curve characterized by an a⁄nity signi¢-
cantly higher than that seen with SGLT1. From
independent measurements, the Km of C1 for KMG
at 350 mV was 0.37 þ 0.05 mM while the equivalent
Fig. 3. Sugar activation of the cotransport current. Currents
were measured in DNA-injected oocytes held at 350 mV with
perfusion of varying external concentrations of di¡erent sugars.
The [Na] was 88 mM and the [sugar] ranged from 200 WM to
20 mM. For each oocyte, currents were ¢rst normalized to
100% = current at 20 mM substrate. For each sugar concentra-
tion, these data were combined from four to six oocytes to pro-
duce mean values (shown with error bars representing S.E.M.).
The combined data were ¢tted to a Michaelis^Menten equation
to derive Km and Imax values. For presentation, the currents
have been normalized with the calculated Imax values set at
100%, in order to better compare the two curves. Closed circles
represent oocytes expressing SGLT1; open circles represent oo-
cytes expressing C1. Glc, glucose; Gal, galactose; 3-OMG, 3-O-
methylglucose.
Fig. 4. Individual sugar a⁄nities of SGLT1 and C1. The a⁄n-
ities of C1 and SGLT1 for the four sugars tested were deter-
mined with oocytes held at 350 mV. All values represent
means þ S.E.M. of the a⁄nity constants measured from four
to six oocytes for both C1 and SGLT1.
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value for SGLT1 was 0.77 þ 0.14 mM, (P6 0.05).
Thus, despite the diminution of the KMG-induced
currents observed by converting SGLT1 to C1, the
chimeric protein is characterized by an increased af-
¢nity for the speci¢c substrate of SGLT1.
3.3. A⁄nities for di¡erent sugars
We examined whether the selectivity amongst
di¡erent substrates (see Fig. 3) known to be trans-
ported by SGLT1 was also altered, indicative of
whether the selectivity of the sugar binding site
was changed. In Fig. 4, the a⁄nity constants of
C1 and SGLT1 for various sugars are shown,
measured at 350 mV. For both SGLT1 and C1,
KD-glucosem 6K
KMG
m 6K
D-galactose
m 6K
3-O-methylglucose
m . In
addition to having the same selectivity sequence of
sugars as seen for SGLT1, the ratio between the
SGLT1 and C1 Km values for any sugar were always
between 2 and 4.2 (average þ S.D. = 3.3 þ 0.4). The
uniform change in a⁄nities produced by altering
the N-terminus of SGLT1 suggests that the modi¢-
cation did not alter the protein’s structural moieties
which di¡erentiate between the sugars used here, de-
spite the overall changes in Km values.
3.4. Na a⁄nities
Fig. 5 illustrates the activation of cotransport cur-
rents by the external Na concentration ([Na]o) in
the presence of 5 mM KMG. This data was analyzed
using the Hill equation. Despite markedly di¡erent
levels of current for SGLT1 and C1 (26 þ 3 nA for
C1 vs. 680 þ 70 nA for SGLT1 at 90 mM Na, n = 7
each), the activation by [Na]o was slightly sigmoidal
(nH = 1.2 for C1 and 1.4 for SGLT1 at 350 mV) for
both cotransporters and the average Km values for
Na were indistinguishable (Km = 25 þ 4 mM for C1
and 31 þ 2 mM for SGLT1). Furthermore, the Na
Km values for SGLT1 and C1 both varied with mem-
brane potential in identical fashion (data not shown).
In comparison, the Na Km value for SMIT, when
perfused with myo-inositol, is slightly higher than
that described for SGLT1 and is almost voltage-in-
dependent [11]. We conclude that Na interacts with
C1 in a manner very similar to that seen with
SGLT1.
3.5. Phlorizin sensitivities
To determine sensitivity to phlorizin, current was
measured from voltage-clamped SGLT1- and C1-ex-
pressing oocytes in the presence of 5 mM KMG, 90
mM NaCl and various concentrations of phlorizin.
Fig. 5. Sodium a⁄nities of SGLT1 and C1. KMG-dependent
currents in C1- and SGLT1-expressing oocytes were measured
with varying external concentrations of Na. The [KMG] was
5 mM and [Na] ranged from 200 WM to 90 mM. Data shown
are the mean þ S.E.M. of currents measured from seven oocytes
for both C1 (open circles) and SGLT1 (closed circles). The cur-
rents have been normalized with respect to the calculated maxi-
mal current at 100% in order to better compare the two curves.
The inset displays the a⁄nity constants derived from a Hill
analysis of the data.
Fig. 6. Phlorizin sensitivity of cotransport currents. The KMG-
induced steady-state current was inhibited by perfusion with ex-
ternal phlorizin in saline Barth’s solution. The holding potential
was 350 mV, the external KMG concentration was 5 mM and
the [phlorizin] ranged from 100 nM to 20 WM. Data shown rep-
resent means þ S.E.M. for C1 (open circles, n = 5) and SGLT1
(closed circles, n = 9). The inset shows the inhibition constants
derived from a competitive inhibition model.
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Fig. 6 shows that increasing the concentration of
phlorizin decreased the KMG-induced steady-state
current. Analysis of the data, using a competitive
inhibition model employing the values for KMG af-
¢nities derived above (0.37 mM for C1 and 0.77 mM
for SGLT1), provided estimates of the apparent Ki
values for phlorizin. As can be seen in Fig. 6, the two
curves are very parallel as can be expected when the
inhibitor Ki has changed in proportion to the sub-
strate Km. The best Ki values ¢tting the data of Fig. 6
are 0.07 þ 0.01 WM for C1 and 0.13 þ 0.01 WM for
SGLT1, i.e. in proportion to the respective Km val-
ues. By comparison, the Ki for SMIT is 64 WM [11].
Thus, as was seen for sugar substrates, replacing the
N-terminus of SGLT1 with that of SMIT increased
the a⁄nity for phlorizin.
3.6. Turnover rates
We sought to determine whether the low level of
currents associated with C1 could be accounted for
by a decrease in the number of transport proteins at
the cell surface. Glucose-induced currents were meas-
ured from oocytes which expressed SGLT1 or C1,
following which radiolabelled phlorizin was used to
detect the surface density of transport molecules
(Fig. 7A). To calculate the number of surface trans-
porters, the cpm count must be corrected for the
di¡erent phlorizin a⁄nities of SGLT1 and C1. This
would generally be done by measuring binding of
labelled phlorizin in the presence of di¡erent concen-
trations of non-labelled phlorizin, but this approach
was unfeasible here due to the low levels of radio-
activity bound to C1-expressing oocytes. In the case
of SGLT1, however, Pz binding could be determined
at di¡erent total concentrations of Pz and the a⁄nity
measured was 0.13 þ 0.08, which was not di¡erent
from the Ki measured in Fig. 6. Therefore, we meas-
ured phlorizin binding to C1-expressing oocytes at a
single tracer concentration of phlorizin and derived
the number of binding sites (Bmax) using the Ki value
obtained from the results shown in Fig. 6, employing
the formulae given below. The current-derived Ki
values for both C1- and SGLT1-expressing oocytes
and the measurements from radiolabelled phlorizin
binding to the oocytes (cpm) were used for calculat-
ing the number of binding sites as follows:
cpm  BmaxPz
K i  Pz 1
Thus, Bmax can be de¢ned as
Bmax  cpmK i  PzPz 2
Although the C1-expressing oocytes shown in Fig.
7A displayed seven times less phlorizin binding
than did SGLT1, the glucose-induced currents in
C1-expressing oocytes were 48 times less than those
in SGLT1-expressing cells. To account for the re-
maining di¡erence in transport activity the turnover
number, obtained by dividing the recorded currents
by the phlorizin binding, must be seven times lower
in C1 than in SGLT1 (Fig. 7B).
We investigated whether the di¡erences in trans-
port activity between SGLT1 and C1 were due to the
altered amino acid sequence and not simply due to
the diminished length of the amino terminus by cre-
ating four truncated SGLT1 mutant proteins. KMG-
dependent currents were measured in oocytes that
were expressing each of the deletion mutants and
compared to those measured with full-length
SGLT1. Deletion mutants SGLT1v2^6, SGLT1v2^
9 and SGLT1v2^14 yielded currents that were indis-
tinguishable from those of full-length SGLT1 (data
Fig. 7. Phlorizin binding to C1 and SGLT1. (A) The level of
phlorizin binding is shown for groups of oocytes alongside the
currents measured from the same oocytes. (B) Turnover rates
for SGLT1 and C1 were derived from the data shown in A.
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not shown). The a⁄nities for Na of these mutant
proteins (SGLT1v2^6, Km = 27 þ 2 mM, n = 4;
SGLT1v2^9, Km = 23 þ 0.3 mM, n = 3; SGLT1v2^
14, Km = 27 þ 2 mM, n = 4) were similar to those
measured for SGLT1 (Km = 31 þ 2 mM). The a⁄n-
ities for glucose were also unchanged by the dele-
tions (SGLT1v2^6, Km = 0.63 þ 0.03 mM, n = 9;
SGLT1v2^9, Km = 0.58 þ 0.02 mM, n = 6;
SGLT1v2^14, Km = 0.52 þ 0.03 mM, n = 6 vs. a Km
of 0.58 þ 0.03 mM for SGLT1). In contrast, further
deletion of amino acids 14^19 (SGLT1v2^19) pro-
duced substrate-dependent currents that were rarely
measurable in oocytes and, when present, were on
the order of 5 nA.
4. Discussion
As compared to other membrane proteins (e.g.
potassium channels), very little is known about the
structure^function relationship of 12^14 transmem-
brane domain cotransporters. Not only is crystal
structure unavailable, but even the general function
of speci¢c portions of the primary sequence remains
largely unknown. One way to gain access to this type
of information is to create chimeric proteins between
homologous cotransporters and to follow speci¢c
perturbations in several characteristic properties. In
the case of the Na-glucose cotransporter family, one
such chimera has been reported (between SGLT1
and SGLT2) which led to the suggestion that the
sugar-binding site was located in the C-terminal
half of the protein [17]. This was further supported
by a study on a truncated SGLT1 where the last ¢ve
C-terminal transmembrane segments were shown to
form a Na-independent glucose transporter [18].
We found that successful chimera production is
severely limited by the apparent fragility of the pro-
tein. Out of 12 chimeras produced, only one trans-
lated an actual chimeric protein which retained some
functionality. In a recent study from our laboratory,
we added three di¡erent epitope tags corresponding
to about 10 amino acids at two di¡erent locations in
the protein sequence and a single combination pro-
duced an active protein [26]. Single amino acid mu-
tations were also found to inactivate the protein and
cause glucose^galactose malabsorption syndrome
[27]. The same type of low success rate in producing
functional mutated transporters was found when a
glycosylation site was introduced at various locations
in the primary sequence in order to establish the
actual membrane topology of the cotransporter [9].
We suspect that the susceptibility of this protein’s
activity to small changes in sequence may be due
to a large change in conformation required of a pro-
tein whose function involves interaction with and
translocation of three substrates; recently the ¢rst
direct observation of this conformational change
was reported [28]. For these reasons, we employed
an in vivo recombination method to create chimeras
between SMIT and SGLT1. This technique has sev-
eral advantages in that it yields a large number of
chimeras in a short time and the site of joining be-
tween the two proteins should be randomly located
within homologous regions. The low rate of success
at obtaining active chimeras prompted us to focus on
comparing many functional characteristics of chi-
mera C1 to those of SGLT1 rather than create addi-
tional chimeras; the low success rate also provides
convincing evidence that a method of creating a rel-
atively large number of random chimeras, as used
here, is preferable to using site-directed mutagenesis
and recombination to directly create chimeras.
4.1. Properties of C1
In the present study, we have compared several
transport properties of C1 to the corresponding
properties of SGLT1. The most intriguing ¢nding is
that the apparent a⁄nity constants, for several types
of sugars as well as for the inhibitor phlorizin, are
increased by a factor of 2^4. On the other hand, the
apparent a⁄nity constants of SGLT1 and C1 for Na,
at a saturating glucose concentration, are identical.
Interpreting apparent a⁄nity constants is not
straightforward in the case of a cotransporter, like
SGLT1, which must go through three binding reac-
tions on each side of the membrane (generating a
minimum of eight di¡erent states). In addition,
although there is agreement that Na binds ¢rst at
the extracellular surface [29], the binding order of
the second Na ion and the glucose molecule is still
debated [4,7,30]. Fig. 8 presents one possible model
as proposed by Bennett and Kimmich [30] and for
which we have recently provided some experimental
evidence [7]. For reasons of clarity, we have com-
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bined the reactions where the Na ions and the glu-
cose molecule are released on the intracellular side.
We have also omitted the pathway corresponding to
the small Na-leak current that corresponds to about
1% of the maximal Na-glucose current. As explained
in the Appendix, the simplest means by which to
explain a higher glucose a⁄nity with a constant Na
a⁄nity (at saturating glucose) is to augment the rate
constant for glucose binding (k23 in Fig. 8), which
would be increased by a factor of 2^4 in the case of
C1 with respect to the corresponding rate constant of
SGLT1. This is fully consistent with the observed
decrease in the phlorizin Ki as the binding of a com-
petitive inhibitor is likely to follow the pathway for
the binding of glucose. Altering the speed at which
glucose may bind to the cotransporter without
changing the binding site itself or its associated dis-
sociation rate constant (k32) explains why four di¡er-
ent substrates with widely varying a⁄nities all dis-
play a⁄nity constants which are increased by a
similar factor. The explanation for the decrease in
turnover rate calculated for C1 is not straightforward
at this point. A decrease in the maximal activity of
the cotransporter must be related to one of the steps
that were lumped together in the transitions from
state 4 to 5 and from state 5 to 1 (see Fig. 8). Sim-
ilarly, the I^V curve obtained at high Na and KMG
concentrations re£ects the voltage dependence of the
same lumped steps. The resemblance noted between
the I^V curve of C1 and SMIT suggests that, in these
two cases, the resulting rate constants can be accel-
erated by hyperpolarization throughout the voltage
range while, in the case of SGLT1, a voltage-insen-
sitive step becomes rate-limiting at potentials more
negative than 375 mV. This also indicates that the
N-terminal region of SGLT1 contains a moiety
which is involved in the saturation of activity as
the membrane potential becomes quite negative.
4.2. Sequence comparison
Within the ¢rst 50 amino acids of SMIT (the
SMIT-derived sequence that is found in C1), the level
of identity between the amino acid sequence of C1
and the corresponding region of SGLT1 is 48%. The
most striking di¡erence between the primary struc-
tures of SGLT1 and C1 is in the extreme N-terminal,
extracellular [9,26,31] region where the initial 26 ami-
no acids of SGLT1 have very little similarity to their
heptapeptide counterpart in SMIT. To examine
whether the di¡erences in functional activity between
C1 and SGLT1 are due to this region of SGLT1 that
is essentially absent from SMIT (and thus C1), we
created a series of mutant forms of SGLT1 which
bore deletions (of 5^18 amino acids) immediately
following the initial methionine. Although amino
acids 2^14 were removed without causing any appar-
ent change to SGLT1 activity, there was very little
KMG-induced current when SGLT1v2^19 was ex-
pressed in Xenopus oocytes (not shown), suggesting
that the pentapeptide 15RPVET19 plays an important
role in the biosynthesis, folding or tra⁄cking of
SGLT1. This indicates that the shorter amino termi-
nus of C1 may explain a portion of the low activity
recorded for the chimera, but it should be noted that
the N-terminal heptapeptide of C1 does contain the
sequence 5LET7, which is similar to part of the pen-
tapeptide described above. This may explain why C1
displays considerably more current than that seen
with SGLT1v2^19.
Binding of radiolabelled phlorizin to the oocytes
showed that the surface density of SGLT1 was ap-
proximately seven times that of C1. The diminished
number of C1 transporters at the plasma membrane
may be due to decreased stability of the RNA or
protein, or to incorrect processing or/and targeting
of C1 to the plasma membrane. Simply switching the
5P untranslated region of SGLT1 for that of SMIT
may a¡ect the level of protein translation since the
Fig. 8. Kinetic model of SGLT1 activity. A kinetic model of
SGLT1 is shown where, for reasons of clarity, the Na leak cur-
rents have been omitted and the intracellular steps have been
combined. Black circles indicate the individual conformational
states.
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initial codon in SMIT is surrounded by a Kozak
consensus sequence inferior to that of SGLT1 [32].
4.3. Comparison with other structure/function
properties of SGLT1
The developing concept around the structure/func-
tion of SGLT1 is that the glucose-binding domain is
mostly comprised of the last 5 transmembrane seg-
ments, while the Na binding sites are possibly located
in the ¢rst half of the protein [17,18]. Although the
N-terminal halves of SGLT1 and related Na co-
transport proteins might be expected to be involved
in the transport of Na, based on their sequence
similarities, the Na a⁄nity of C1 displays the
same magnitude and voltage-dependence (data not
shown) as does that of SGLT1. By comparison,
SMIT has a higher Na a⁄nity and the Km value
is less voltage-dependent. These data suggest that the
initial seventy amino acids of the N-terminal region
of SGLT1, which are replaced in C1 by the equiva-
lent region of SMIT, are not immediately involved in
the binding of Na, in agreement with the results of
Lo and Silverman [31] which suggested that the re-
gion between transmembrane helices IV and V plays
a role in Na binding and voltage-sensing. On the
other hand, our observation that the replacement of
the N-terminus has increased the glucose apparent
a⁄nity of SGLT1 might appear contradictory to
the previous suggestion that the last 5 transmem-
brane spanning segments constitute the glucose
transporter. However, our kinetic analysis (see Ap-
pendix) and the observation that phlorizin and four
di¡erent substrates have experienced the same mod-
i¢cation in their respective a⁄nity indicates that it is
the access to the binding site and not the binding site
itself that is modi¢ed in C1 vs. SGLT1.
This study has shown that replacement of the ¢rst
69 amino acids of SGLT1 with the corresponding 50
amino acids of SMIT diminished the Km for KMG
and reduced the turnover rate by a factor of 7, but
left the Na a⁄nity intact, indicating that the Na
binding site is unlikely to be located in the N-termi-
nal region of SGLT1 that is di¡erent in C1. How-
ever, the speci¢city of binding amongst sugars was
unchanged, suggesting that the sugar binding site
itself was unaltered and that the extracellular N-ter-
minal plays a role in favoring accessibility to the
binding site.
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Appendix
To consider the e¡ects of replacing the amino ter-
minal region of SGLT1 with that of SMIT, we em-
ploy a simpli¢ed kinetic model (Fig. 8). Using the
program of Falk et al. [33] to solve a set of steady-
state reactions like those shown in Fig. 8, the Na
in£ux is given by
JNa  C1WGlcWNa
2
C6  C5Na C3GlcNa C4Na2  C2WGlcWNa2:
A1
The de¢nition of each constant term ‘Cn’ is given in
Table 1. The apparent a⁄nity constant for the sub-
strate (Glc) can be de¢ned as
KGlcm 
C6  C5Na C4Na2
C3Na C2Na2 : A2
Under our experimental conditions, where KGlcm is
measured in the presence of 90 mM Na (three times
its apparent a⁄nity at high [Glc]), it is useful to take
Table 1
Constants used in modeling SGLT1 kinetics
Model
constant
De¢nition
C1 = k12 k23 k34 k45 k51
C2 = k12 k23 k34 (k45+k51)
C3 = k23 (k15 k34 k45+k12 k43 k51+k12 k45 k51+
k34 k45 k51)
C4 = k12 k34 k45 k51
C5 = k15 k21 k34 k45+k12 k32 k43 k51+
k12 k32 k45 k51+k21 k34 k45 k51
C6 = k21 k32 (k43+k45)(k12+k51)
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the limit of Eq. A2 for very high extracellular [Na],
lim
Na!r
KGlcm 
C4
C2
 k45k51
k23k45  k51: A3
The apparent a⁄nity constant for Na can be easily
derived when Glc is assumed to be high in Eq. A1.
This apparent Na a⁄nity (at high Glc) is
lim
Glc!r
KNam 
C3
C2
 k15k34k45  k12k43k51  k12k45k51  k34k45k51
k12k34k45  k51 :
A4
Given Eqs. A3 and A4, it can be seen that KGlcm is
inversely proportional to k23, the forward rate con-
stant for substrate binding, while KNam is completely
independent of k23. Then, the simplest way to change
the KGlcm by a factor of 3 without changing K
Na
m is to
act on k23. Other possibilities certainly exist, but they
would generally require a certain combination of rate
constants that makes KNam insensitive to this modi¢-
cation.
Another strong support for our contention that k23
explains the observed changes in substrate a⁄nity is
the observation of a parallel change in the phlorizin
inactivation constant (Ki). Phlorizin is recognized as
a competitive inhibitor against glucose for Na-glu-
cose cotransport. Based on the equations describing
competitive inhibition, Pz a¡ects the substrate appar-
ent a⁄nity constant as follows:
KGlcm  K Glcm Pz0  1
Pz
K i
 
A5
Given the model shown in Fig. 8, the inhibition con-
stant for Pz in the presence of a high Na concentra-
tion is simply given by
K i  k62k26 A6
Fig. 6 shows that the phlorizin Ki must change in
proportion with the substrate Km in order to gener-
ate identical inhibition curves for C1 and SGLT1.
The simplest explanation is that k26 for Pz, which
corresponds to k23 for substrate binding, is increased
by a factor of 2^4. Interestingly, the measurement of
Ki for Pz does not depend on the other rate constants
of the cycle.
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